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ABSTRACT
We use polygenic risk scores (PRSs) for schizophrenia (SCZ) and bipolar disorder (BPD) to predict smoking, and addic-
tion to nicotine, alcohol or drugs in individuals not diagnosed with psychotic disorders. Using PRSs for 144 609 sub-
jects, including 10 036 individuals admitted for in-patient addiction treatment and 35 754 smokers, we find that
diagnoses of various substance use disorders and smoking associate strongly with PRSs for SCZ (P = 5.3 × 1050–
1.4 × 106) and BPD (P = 1.7 × 109–1.9 × 103), showing shared genetic etiology between psychosis and addiction.
Using standardized scores for SCZ and BPD scaled to a unit increase doubling the risk of the corresponding disorder, the
odds ratios for alcohol and substance use disorders range from 1.19 to 1.31 for the SCZ-PRS, and from 1.07 to 1.29 for
the BPD-PRS. Furthermore, we show that as regular smoking becomes more stigmatized and less prevalent, these bi-
ological risk factors gain importance as determinants of the behavior.
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INTRODUCTION
Addiction to tobacco, alcohol or drugs is frequently a
co-morbidity of other psychiatric disorders, including
schizophrenia (SCZ) and bipolar disorder (BPD) (Cerullo
& Strakowski 2007; Margolese et al. 2004). The high
rate of smoking among SCZ patients is well known,
and increased rates of substance use disorders and
smoking are observed among their first-degree relatives
(Smith et al. 2008). The situation is similar for BPD,
with over 40 percent co-morbidity of substance use
disorders (Cerullo & Strakowski 2007) and high
smoking rates as well (Jackson et al. 2015). These high
co-morbidities call for an explanation, but separating
cause and consequence has remained a challenge, the
case of cannabis use and the onset of psychosis being
a pertinent example (Marconi et al. 2016). Substance
use can be a consequence of underlying psychiatric
disorders, i.e. represent a form of self-medication
(Khantzian 1985), thereby increasing risk of addiction.
Alternatively, substance use, particularly excessive use,
may increase the risk of later developing various psychi-
atric disorders (Kenneson, Funderburk & Maisto 2013).
Both SCZ and BPD have a prevalence of about 1 per-
cent and are associated with premature mortality and
low quality of life (McGrath et al. 2008; Blanco et al.
2016). Dual diagnoses of psychosis and a substance
use disorder are associated with severity and chronicity
of both conditions (Hartz et al. 2014). It is of great pub-
lic health importance to understand these relationships,
as smoking and substance use have consequences that
greatly influence health and life expectancy of individ-
uals with mental disorders (Osborn et al. 2007). In
2012, 3.3 million deaths, or nearly six percent of all
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global deaths, were attributable to alcohol consumption
(http://www.who.int/substance_abuse/publications/global_
alcohol_report/en/), and tobacco smoking is a major
cause of preventable deaths, claiming approximately six
million victims per year (http://www.who.int/tobacco/
global_report/2015/en/).
Addictions to alcohol, nicotine and illicit drugs are her-
itable disorders influenced bymany variants of small effect
(Goldman, Oroszi & Ducci 2005; Manolio et al. 2009), as
are SCZ and BPD (PGC-Bipolar-Disorder-Working-Group
2011; PGC-Schizophrenia-Working-Group 2014). Using
polygenic risk scores (PRSs) from an ensemble of common
sequence variants of small effects can aid in elucidating
whether co-morbidity relationships reflect shared genet-
ics. In particular, the PRS methodology can be applied to
subjects who do not have the psychiatric disorders, pro-
viding separation of the effect of the diseases themselves
from those of the underlying genetic risk factors. PRSs
and LD score regression (Bulik-Sullivan et al. 2015b) have
revealed shared genetic etiology between SCZ and BPD
(Bulik-Sullivan et al. 2015a), between psychosis and can-
nabis use (Power et al. 2014), and use of other substances
(Bulik-Sullivan et al. 2015a). Given these relationships,
we hypothesized that the SCZ- and BPD-PRSs could be
used to reveal the extent of genetic overlap between these
psychotic disorders and substance use disorders.
METHODS
Subjects
This study involved 144 609 Icelandic subjects. The age
and sex distributions are provided in Table 1. The study
was approved by the Icelandic Data Protection Authority
and the National Bioethics Committee. All participating
subjects who donated blood also signed informed con-
sent. Personal identities of the patients and biological
samples were encrypted by a third-party system provided
by the Icelandic Data Protection Authority. Controls were
recruited as a part of various genetic research programs
at deCODE and were not specifically screened for psychi-
atric disorders or substance use disorders. Individuals di-
agnosed with SCZ or BPD were excluded from controls.
Smoking phenotypes
The Fagerström Test for nicotine dependence (FTND)
(Heatherton et al. 1991) is a standard questionnaire de-
signed to assess the intensity of physical addiction to nic-
otine. FTND data were obtained from questionnaires
answered by participants in deCODE’s study of nicotine
dependence (ND) (2004–2014)(Thorgeirsson et al.
2008). Responses to FTND questions generate a score of
0–10, with higher scores representing greater ND
(Heatherton et al. 1991). Information on smoking
quantity (SQ) was also utilized, but SQ was available from
a standardized smoking questionnaire used in deCODE’s
studies that asks: ‘How many cigarettes per day do/did
you smoke on average (on most days)?’ This means that
current smokers answer about their current consump-
tion and former smokers refer to their consumption in
the past. In cases where multiple records were available,
we recorded the maximum reported cigarettes per day
(CPD). Never smokers were excluded from studies of
CPD. The SQ was categorized into four levels, (1–10,
11–20, 21–30 and 31+ CPD). Information on ever-
smoking versus never-smoking was obtained from ques-
tionnaires, typically asking about regular daily smoking
for an extended period of time, most often 1 year. Subjects
with SCZ or BPD diagnoses were excluded from smoking
samples (Table 1).
Substance use disorders
Subjects were recruited through the largest addiction
treatment center in Iceland, the SAA-National Center of
Addiction Medicine (Tyrfingsson et al. 2010). All patients
were admitted for an in-patient detoxification treatment
and rehabilitation program. Substance use disorder
Table 1 Number of cases and demographic data.
Phenotype n (% women) Mean age (SD)
PRS phenotypes
SCZ 600 (35.7) 61.31 (16.77)
BPD 772 (63.3) 69.88 (18.67)
Smoking
FTND 4609 (52.5) 57.26 (12.07)
FTND wo. adm. 2940 (63.5) 57.21 (11.16)
CPD 35 754 (61.8) 65.75 (16.82)
CPD wo. adm. 31 511 (64.8) 66.38 (16.96)
Ever-smoking versus
never-smokinga
35 567 (61.6) 65.79 (16.83)
Ever-smoking versus
never-smoking wo. adm.a
31 330 (64.6) 66.42 (16.97)
Substance use disorders
Alcohol use disorder 8701 (32.7) 55.74 (15.45)
Amphetamine use disorder 1744 (33.5) 41.17 (11.52)
Cocaine use disorder 645 (28.5) 38.84 (10.25)
Cannabis use disorder 1896 (29.7) 40.34 (11.76)
Opioid use disorder 501 (49.1) 51.13 (13.12)
Sedative use disorder 1625 (51.8) 54.91 (14.89)
EO 2810 (34.7) 39.56 (10.13)
Number of admissions 10 036 (32.5) 56.87 (16.47)
Total sample 144 609 (53.7) 56.60 (20.90)
BPD, bipolar disorder; CPD, cigarettes per day; EO, early onset of alcohol
and/or substance use disorder; FTND, Fagerström Test of nicotine depen-
dence; PRS, polygenic risk scores; SCZ, schizophrenia; wo. adm., without
admission to the addiction treatment program. aFor ever-smoking versus
never-smoking, the number of ever-smokers is listed, and the control
group consisted of 17 145 never smokers.
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diagnoses were made by clinicians using the Diagnostic
and Statistical Manual of Mental Disorders (DSM) system.
The diagnoses were made between the years 1977 and
2014, most using DSM-IIIR and DSM-IV. This is a treat-
ment sample, and most of the patients have severe sub-
stance use disorders, scoring well above the thresholds
for diagnosis of substance dependence in DSM-IIIR and
DSM-IV. Co-morbidity is high (Tyrfingsson et al. 2010),
and patients diagnosed with more than one substance
use disorders were included. The substances considered
in this study were as follows: alcohol, amphetamine, can-
nabis, cocaine, opioids and sedatives (Table 1). Subjects
diagnosed with SCZ or BPD were excluded.
Psychiatric disorders
The Icelandic SCZ sample consisted of 600 cases. Diagno-
ses were assigned according to research diagnostic
criteria (Spitzer, Endicott & Robins 1978) through the
use of the Schedule for Affective Disorders and Schizo-
phrenia Lifetime Version. Subjects diagnosed with BPD
were excluded (Table 1). The Icelandic BPD sample
consisted of 772 cases. Diagnoses were assigned accord-
ing to Research Diagnostic Criteria, DSM-IV, ICD-9 or
10 and DSM-III. Cases diagnosed with SCZ were ex-
cluded (Table 1).
Genotyping and imputation
Genotyping was carried out using Illumina chips. Quality
control, long-range phasing and imputation were carried
out as previously described (Gudbjartsson et al. 2015).
Statistical analysis
Polygenic risk scores for SCZ and BPD were tested for as-
sociation with SCZ and BPD in Iceland, and both PRSs
also tested for association with smoking, ND, alcohol de-
pendence and substance use disorders. Individuals diag-
nosed with SCZ or BPD were excluded from the analyses
for ND, alcohol dependence and substance use disorder.
Association to case–control and quantitative trait pheno-
types were computed using logistic and linear regression,
respectively. For each case–control phenotype studied,
the remainder of the sample was used as controls. All
models were adjusted for sex, year of birth and place of
birth. Interaction between sex and PRS was tested by in-
cluding a sex × PRS term in the regression models. If the
interaction term was significant (P < 0.05), the sample
was stratified by sex and tested for association with the
PRS, without sex as a covariate. Interaction between
PRS and year of birth was similarly tested by including
a PRS × year of birth term in the regression models. Sub-
jects within the CPD and ever-smoking versus never-
smoking phenotypes were additionally stratified by
decade of birth to determine the contribution of SCZ ge-
netic risk to smoking/ND as smoking rates change in
the general population. The variance explained (R2) by
polygenic scores was computed using Nagelkerke’s
pseudo-R2 for case–control phenotypes. The R2 of the
model including only covariates was subtracted from
the R2 of the full model (polygenic scores and covariates).
For quantitative-trait phenotypes, R2 was computed
using the deviance of the full model divided by the devi-
ance of the model including only covariates. Effects and
odds ratios (ORs) are reported for one unit change in
polygenic score. To account for inflation due to related-
ness and population stratification, the test statistics for
each analysis was divided by an inflation factor estimated
from LD score regression (Bulik-Sullivan et al. 2015b).
Polygenic risk scores
Polygenic risk scores were obtained using P-values and
log OR from a subset of single nucleotide polymorphisms
(SNPs) included in genome-wide association studies
(GWASs) of the Psychiatric Genetics Consortium (PGC-Bi-
polar-Disorder-Working-Group 2011; PGC-Schizophre-
nia-Working-Group 2014). The subsets were prepared
by the SCZ and BPD working groups using P-value in-
formed clumping. Neither of the GWAS included Icelan-
dic data. The SCZ and BPD subsets contained 102 636
and 108 834 SNPs, respectively. Selecting SNPs in the
Icelandic data with minor allele frequency ≥0.01, impu-
tation info ≥0.8 and excluding G/C and A/T SNPs,
84 204 and 72 457 SNPs of the SCZ and BPD subsets, re-
spectively, matched the Icelandic data. The SCZ-PRS was
computed from the 2014 meta-analysis of the schizophre-
nia working group of the PGC (36 989 cases and 113 075
controls) (https://www.med.unc.edu/pgc/files/resultfiles/
scz2.prs.txt.gz), and the BPD-PRS was computed from the
2011 meta-analysis of the BPD working group (7481 cases
and 9250 controls), i.e. pgc.bip.clump.2012–04.txt from
(https://www.med.unc.edu/pgc/files/resultfiles/pgc.
bip.2012-04.zip). Polygenic scores were computed at 500
equally spaced P-value thresholds in the range 0.001–0.5.
The association between the PRS and its corresponding dis-
order within the Icelandic population was tested for each P-
value threshold using logistic regression, including sex, age
and place of birth as covariates (Supporting Information Fig.
S3). The strongest association and the highest explained
variance were obtained at P-value threshold of 0.118 for
SCZ-PRS and 0.190 for BPD-PRS. The SCZ-PRS explained
4.67 percent of the variance in schizophrenia
(P = 1.4 × 1067), and the BPD-PRS explained 0.90 per-
cent of the variance in BPD (P = 1.3 × 1018). The SCZ-
PRS and BPD-PRS at these P-value thresholds have a mod-
erate degree of correlation, with an R2 of 4.38 percent. The
SCZ-PRS and BPD-PRS were centered by subtracting the
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mean and multiplied by 0.3399 and 0.0827, respectively,
such that one unit increase in PRS results in an OR of 2
for their corresponding disorder in Iceland. The distribution
of the PRSs before and after scaling is shown in the
Supporting Information Fig. S2. Note that the SCZ-PRS
has a broader distribution than the BPD-PRS; therefore, of
the controls, 18 percent have a SCZ-PRS above 1 while
1.8 percent have a BPD-PRS above 1.
RESULTS
In this study, we used a sample of 144 609 Icelandic in-
dividuals to estimate for smoking and substance use dis-
orders the genetics shared with SCZ and BPD (Table 1).
We computed PRSs using summary data from the
meta-analyses of the schizophrenia and BPD working
groups of the Psychiatric Genomics Consortium, neither
of which included Icelandic data (PGC-Bipolar-Disorder-
Working-Group 2011; PGC-Schizophrenia-Working-
Group 2014) (Methods and Supporting Information).
The SCZ-PRS and BPD-PRS explained 4.67 percent
and 0.90 percent of the risk variance in their correspond-
ing disorders in Iceland (Table 2). For subsequent analy-
ses, we scaled the PRSs such that each unit increase
doubles the risk of the corresponding disorder (Table 2).
We excluded known BPD and SCZ cases from the
analyses of the correlation of the PRSs with addiction
and smoking. We computed the PRSs for individuals di-
agnosed with alcohol and substance use disorders at the
SAA National Center of Addiction Medicine (http://saa.
is/english/saa-national-center-of-addiction-medicine) as
well as controls and found that higher SCZ-PRS associ-
ated with increased risk of alcohol and substance use dis-
orders (P = 7.8 × 109–5.3 × 1050). Higher BPD-PRS
was also associated with increased risk of alcohol use dis-
order (P = 1.7 × 109) and sedative use disorder
(P = 5.9 × 106) (Table 2). The effect for alcohol and
substance use disorders range from 1.19 to 1.31, for
the SCZ-PRS, and from 1.07 to 1.29 for the BPD-PRS.
Early onset (EO) of substance use problems and a chronic
relapsing pattern are the hallmarks of severe addiction.
Similarly, low age at first treatment and repeated admis-
sions for treatment are indicators of addiction severity.
To assess the PRSs as predictors of severity of addiction,
we studied individuals first admitted at age 25 or younger
(EO, Early Onset) and number of admissions. Higher SCZ-
PRS was associated with increased risk of EO (OR = 1.23,
P = 7.7 × 1024) and increased number of admissions
(β = 0.26, P = 4.7 × 109), and higher BPD-PRS was as-
sociated with increased risk of EO (OR = 1.16,
P = 1.9 × 103).
Substance abuse and addiction have higher preva-
lence in men than women (Becker & Hu 2008). To ex-
plore sex-effects, we tested for an interaction between
sex and PRS and found significant interactions
(P < 0.05) for SCZ-PRS in alcohol and cocaine use disor-
ders. Sex-stratified analysis revealed 1.37 and 1.94 times
larger effect for SCZ-PRS on alcohol and cocaine use dis-
order, respectively, in women (Supporting Information
Table S1).
Table 2 Associations between polygenic scores and phenotypes.
SCZ-PRS BPD-PRS
Case/control OR (95% CI) R2 [%] P OR (95% CI) R2 [%] P
SCZ 2.00 (1.85–2.16) 4.67 1.4 × 1067 1.73 (1.44–2.08) 0.53 4.4 × 109
BPD 1.35 (1.26–1.44) 0.92 4.8 × 1019 2.00 (1.71–2.33) 0.90 1.3× 1018
Alcohol UD 1.19 (1.16–1.22) 0.57 5.3 × 1050 1.18 (1.12–1.24) 0.09 1.7 × 109
Amphetamine UD 1.27 (1.21–1.33) 0.67 7.3 × 1025 1.07 (0.97–1.18) 0.01 0.185
Cocaine UD 1.29 (1.20–1.39) 0.62 8.2 × 1012 1.13 (0.95–1.34) 0.03 0.159
Cannabis UD 1.23 (1.18–1.29) 0.49 1.1 × 1019 1.14 (1.03–1.26) 0.04 0.011
Opioid UD 1.27 (1.17–1.38) 0.54 7.8 × 109 1.24 (1.03–1.50) 0.08 0.024
Sedative UD 1.31 (1.25–1.37) 0.89 9.8 × 1030 1.29 (1.15–1.44) 0.14 5.9 × 106
EO 1.23 (1.18–1.28) 0.54 7.7 × 1024 1.16 (1.06–1.27) 0.05 1.9 × 103
Ever-smoking versus
never-smoking
1.07 (1.05–1.09) 0.19 1.5 × 1012 1.00 (0.98–1.02) <0.01 0.917
Quantitative β (95% CI) R2 [%] P β (95% CI) R2 [%] P
FTND 0.16 (0.09–0.22) 0.56 1.4 × 106 0.26 (0.11–0.41) 0.27 7.9 × 104
CPD 0.24 (0.15–0.33) 0.08 1.8 × 107 0.20 (0.01–0.41) 0.01 0.056
Number of admissions 0.26 (0.17–0.35) 0.35 4.7 × 109 0.09 (0.12–0.30) 0.01 0.403
To account for multiple testing, the significance level was set to 0.05/20 = 2.5 × 10
3
. BPD, bipolar disorder; CPD, cigarettes per day; EO, early onset of
addiction as assessed by admission to in-patient addiction treatment before reaching the age of 26 years; FTND, Fagerström Test of nicotine dependence;
PRS, polygenic risk scores; UD, use disorder; SCZ, schizophrenia. Ever-smoking was assessed by ever smokers against never smokers. The estimate for CPD
corresponds to number of cigarettes. To facilitate comparison of effects, the PRSs were scaled to give an OR of 2 for their corresponding disorder.
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Next, we tested the SCZ-PRS and BPD-PRS for associ-
ation with ND, assessed by the FTND, and its proxy, CPD.
Higher SCZ-PRS was associated with increasing FTND
(β = 0.16, P = 1.4 × 106) and CPD (β = 0.24,
P = 1.8 × 107), while higher BPD-PRS was only associ-
ated with increasing FTND (β = 0.26, P = 7.9 × 104)
(Table 2). When individuals admitted to treatment for al-
cohol or drug addiction were excluded, only the associa-
tion between SCZ-PRS and CPD remained significant
(Supporting Information Table S2). The fraction of sub-
jects treated for addiction in the FTND and CPD samples
is about 36 percent and 12 percent, respectively, perhaps
explaining why the effect of the SCZ-PRS changes less for
CPD, in comparison with that for FTND, when treated in-
dividuals are excluded (Table 2 and Supporting Informa-
tion Table S2). Smoking and nicotine addiction are much
more prevalent among individuals with alcohol and sub-
stance use disorders. Treated subjects have higher CPD
(β = 4.9 CPD, P = 2.6 × 10224), higher FTND
(β = 0.28 FTND, P = 2.8 × 1090) and among smokers,
higher SCZ-PRSs (OR = 1.16, P = 2.6 × 1025). The as-
sociation of the SCZ-PRS with smoking and ND might
therefore be primarily through an effect on the risk of al-
cohol or substance use disorders (Supporting Information
Table S2). Ever smokers have higher SCZ-PRS than never
smokers (OR = 1.07, P = 1.5 × 1012) (Table 2), and the
difference remained significant (OR = 1.05,
P = 5.6 × 107) after removing individuals admitted to
treatment (Supporting Information Table S2). However,
it stands to reason that individuals with substance use
disorders that have not been diagnosed/treated would
also contribute strongly to the correlation with smoking
and ND.
There has been about threefold reduction in the
smoking rate in the general Icelandic population over
the last three decades (http://www.statice.is/statistics/
society/health/lifestyle-and-health/), providing a
possibility to explore the effects of increased smoking re-
strictions (legal and social) on the relationships between
the psychosis PRSs and smoking behavior. Stratifying
the deCODE smoking sample by decade of birth showed
the fraction of ever-smokers dramatically decreasing for
subjects born after 1960 (Fig. 1). Interaction between
SCZ-PRS and year of birth in smoking tested significant
(P = 5.01 × 104), and analyzing the association to
SCZ-PRS showed the OR increasing with decade of birth
(Fig. 1). The contribution from SCZ-PRS to the risk of
smoking discernibly increases as the smoking rate de-
clines in the population. This is in agreement with the
observed increased psychiatric co-morbidity among cur-
rent smokers (Talati, Keyes & Hasin 2016). Excluding
subjects with addiction treatment admission did not
change the trend between OR and decade of birth
(Supporting Information Fig. S1), suggesting the in-
creasing OR with decade of birth is not simply due to bi-
ased distribution of subjects treated for addiction. As
smoking is a risk factor for many of the disorders studied
at deCODE, our ever-smoking versus never-smoking
sample is biased towards smokers, explaining the high
prevalence for ever-smoking (Fig. 1).
A moderate degree of correlation, with an R2 of
4.38 percent, was observed between the SCZ-PRS and
BPD-PRS. Only alcohol use disorder was nominally
associated (OR = 1.09, R2 = 0.59 percent,
P = 2.7 × 103) with BPD-PRS when including SCZ-
PRS as a covariate. This suggests that the observed risk
to smoking and substance use disorder from BPD-PRS is
largely explained by a genetic basis common to SCZ and
BPD. We note that SCZ-PRS is a slightly better predictor
for BPD than BPD-PRS (Table 2). However, the BPD-
PRS is derived from a less powered meta-analysis and
only explains 0.90 percent of the variance in BPD in
Iceland, which is about 20 percent of that explained
by SCZ-PRS in SCZ.
Figure 1 Prevalence of self-re-
ported ever-smoking and odds ratio
of schizophrenia polygenic risk scores
(PRSs) for ever-smoking by decade
of birth. Prevalence of self-reported
ever-smoking by decade of birth is
shown in blue (right y-axis). The odds
ratio (OR) of SCZ-PRSs for ever-
smoking is shown in red (left y-axis).
The 95% CI for OR is depicted by
black error bars
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DISCUSSION
Our results support the notion of common genetic roots
of the observed co-morbidity between addiction and psy-
chotic disorders SCZ and BPD, as opposed to solely being a
direct consequence. This conclusion has some similarity
with the outcome from analyses of twin data for addic-
tion and common psychiatric disorders, such as depres-
sion and anxiety disorders, suggesting that the patterns
of lifetime co-morbidity result largely from the effects of
genetic factors (Kendler et al. 2003). However, demon-
strating shared genetics does not necessarily point to true
biological pleiotropy, and here, various scenarios involv-
ing mediated pleiotropy are possible (Gage et al. 2016).
It can be rather difficult to dissect such relationships, as
evidenced by the case of CHRNA5–CHRNA3–CHRNB4
locus, smoking and lung cancer (Gage et al. 2016). The
correlation of the psychosis PRSs with both addiction
and creativity (Power et al. 2015) also brings up the issue
of the relationship between addiction and creativity.
Brendan Behan was not the only ‘drinker with a writing
problem’, and it is no secret that many of the most crea-
tively talented people of arts and letters also battle addic-
tion. Further studies are required to understand the
genetics of these intriguing relationships more fully. Joint
analyses utilizing PRSs based on well-powered GWAS
studies, for SCZ and BPD as well as PRSs for both addic-
tion and depression/anxiety disorders, will undoubtedly
be informative. Results from additional large GWAS stud-
ies may pave the way to bidirectional Mendelian random-
ization studies aimed at dissecting the causal pathways.
We note that risk to substance use disorders seems to
be slightly less for the BPD-PRS than the SCZ-PRS
(Table 2). However, this could easily be due to the BPD-
PRS being derived from a less powered meta-analysis.
We also observed a difference between the sexes, with
the SCZ-PRS clearly conferring higher risk in women
than men for alcohol and cocaine use disorders. Our pre-
vious studies of the familiality of addiction in this sample
found higher familiality for women compared with men
(Tyrfingsson et al. 2010). While the increased familiality
could be due to either genetics or common environment
(the strong influence the mother has on her children),
addiction is more prevalent among men, and this might
be indicative of a higher barrier to develop addiction
among women (Prescott, Aggen & Kendler 1999; Pres-
cott 2002) and/or a higher barrier to seeking treatment.
A higher liability threshold is a likely explanation for the
increased risk conferred by the SCZ-PRS in women in our
sample, with men perhaps being more susceptible to the
effects of environment.
It is of special interest that the impact of the SCZ liabil-
ity score on smoking behavior seems to be on the rise as
the overall prevalence of smoking declines. Psychiatric
vulnerability is increasing among regular smokers. First,
smoking rates for both SCZ and BPD patients remain
quite high, while the population prevalence of smoking
drops. This contributes to increased psychiatric co-
morbidity among current smokers and in younger birth
cohorts, as has been observed (Talati et al. 2016). Second,
we have shown here that a similar trend is observed for
those within the population not diagnosed with SCZ or
BPD but having high PRSs for SCZ or BPD. These obser-
vations have considerable implications for public health
programs in that anti-smoking measures and smoking
cessation programs may need to be tailored towards mod-
ifying the smoking behaviors of both psychiatric patients
and those among the population that have high psycho-
sis PRSs. Many view regular smoking simply as a bad
habit, but our current findings increasingly cast the be-
havior as a psychiatric condition sharing genetic risk
with SCZ and BPD.
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